https://www.selleckchem.com/pr....oducts/gf109203x.htm
RESULTS Study A median OS 11.7 (durvalumab) versus 6.8 (SoC) months hazard ratio (HR) 0.63 [95% confidence interval (CI), 0.42-0.93]; median PFS 3.8 (durvalumab) versus 2.2 (SoC) months [HR 0.71 (95% CI, 0.49-1.04)]. Study B median OS 11.5 (durvalumab + tremelimumab) versus 8.7 (SoC) months [HR 0.80 (95% CI, 0.61-1.05); P = 0.109]. Median PFS of 3.5 months for both groups [HR 0.77 (95% CI, 0.59-1.01); P = 0.056]. Treatment-related grade 3/4 adverse events 9.7% (durvalumab) and 44.4% (SoC; study A) and 22.0% (durvalumab + tremelimumab)
Synes godt om
Kommentar
Del
